These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34916092)

  • 1. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.
    Mehta K; Spaink HP; Ottenhoff THM; van der Graaf PH; van Hasselt JGC
    Trends Pharmacol Sci; 2022 Apr; 43(4):293-304. PubMed ID: 34916092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
    Hawn TR; Shah JA; Kalman D
    Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy.
    Mehta K; Guo T; Wallis RS; van der Graaf PH; van Hasselt JGC
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0036622. PubMed ID: 35862740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host factors subverted by
    Kalra R; Tiwari D; Dkhar HK; Bhagyaraj E; Kumar R; Bhardwaj A; Gupta P
    Int Rev Immunol; 2023; 42(1):43-70. PubMed ID: 34678117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-directed therapy to combat mycobacterial infections.
    Kilinç G; Saris A; Ottenhoff THM; Haks MC
    Immunol Rev; 2021 May; 301(1):62-83. PubMed ID: 33565103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can We Exploit Inflammasomes for Host-Directed Therapy in the Fight against
    Cebani L; Mvubu NE
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
    Leukes V; Walzl G; du Plessis N
    Front Immunol; 2020; 11():451. PubMed ID: 32269568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
    Park HE; Lee W; Shin MK; Shin SJ
    Front Immunol; 2021; 12():703060. PubMed ID: 34262571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment.
    Kim YR; Yang CS
    J Microbiol Biotechnol; 2017 Sep; 27(9):1549-1558. PubMed ID: 28683527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis.
    Saini S; Gangwar A; Sharma R
    Microbiol Res; 2023 Oct; 275():127466. PubMed ID: 37531813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances
    Moreira JD; Koch BEV; van Veen S; Walburg KV; Vrieling F; Mara Pinto Dabés Guimarães T; Meijer AH; Spaink HP; Ottenhoff THM; Haks MC; Heemskerk MT
    Front Immunol; 2020; 11():36. PubMed ID: 32117228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections.
    Heemskerk MT; Korbee CJ; Esselink JJ; Dos Santos CC; van Veen S; Gordijn IF; Vrieling F; Walburg KV; Engele CG; Dijkman K; Wilson L; Verreck FAW; Ottenhoff THM; Haks MC
    Sci Rep; 2021 Oct; 11(1):19634. PubMed ID: 34608194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
    Zumla A; Rao M; Dodoo E; Maeurer M
    BMC Med; 2016 Jun; 14():89. PubMed ID: 27301245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.
    Zhao L; Fan K; Sun X; Li W; Qin F; Shi L; Gao F; Zheng C
    Front Immunol; 2023; 14():1305325. PubMed ID: 38259491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of host-directed therapies on the pathology of tuberculosis.
    Tsenova L; Singhal A
    J Pathol; 2020 Apr; 250(5):636-646. PubMed ID: 32108337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating Iron for Metabolic Support of TB Host Defense.
    Phelan JJ; Basdeo SA; Tazoll SC; McGivern S; Saborido JR; Keane J
    Front Immunol; 2018; 9():2296. PubMed ID: 30374347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remembering the Host in Tuberculosis Drug Development.
    Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
    J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.